Alliance for Clinical Trials in Oncology:

The clinical trial highlighted in this report is entitled “Phase III trial of post-surgical single fraction stereotactic radiosurgery (SRS) compared with Fractionated SRS for Resected metastatic brain disease.” SRS is commonly used as adjuvant therapy after surgery for brain metastasis, however the ideal number of fractions remains unclear. The primary outcome is comparison of local control between the two adjuvant radiation techniques (single fraction vs 3-5 fractions) up to 2 years after treatment. Target enrollment is 208 patients. Neurosurgeons who routinely see patients with brain metastases may be interested in this trial as it impacts treatment paradigms offered to patients. PI is Paul Brown, MD.

Further information regarding this clinical trial can be obtained from the Alliance website at allianceforclinicaltrialsinoncology.org or clinicaltrials.gov.  A list of ongoing trials sponsored by the Alliance can be accessed via the Alliance website.

The spring Alliance for Clinical Trials in Oncology meeting is a hybrid in person/virtual meeting Saturday, May 14, 2022 in Chicago, IL.

J. Bradley Elder, MD

Liaison to Alliance for Clinical Trials in Oncology